Pharmacy Prof Explains Properties of New Pain Pill Approved by FDA
On the heels of the U.S. Food and Drug Administration's approval of an oxycodone pill designed to deter abuse, pharmacy professor Daniel Hussar, PhD, at University of the Sciences in Philadelphia, was featured on KYW Newsradio to explain the drug's properties.
Purdue Pharma's new drug Targiniq ER is an extended release tablet that combines oxycodone — the active ingredient in OxyContin — with the drug naloxone. FDA regulators approved the drug for daily, round-the-clock pain that does not respond to other medications.
If abusers crush these tablets for snorting or injecting, naloxone blocks the euphoric effects of oxycodone, making the drug more difficult to abuse. Naloxone is currently used to reverse the overdose effects of opioids and highly addictive painkilling drugs, including morphine, methadone, codeine and others.